Blog

Matthew Kurian: Highlights from Day 1 at ASCO25’s Metastatic Breast Cancer Data that stood out

Matthew Kurian/youtube.com

Jun 1, 2025, 10:03

Matthew Kurian: Highlights from Day 1 at ASCO25’s Metastatic Breast Cancer Data that stood out

Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:

“Day 1 at ASCO25 — What a start!

Yesterday, I was grateful and energized to kick off the meeting with a full slate of panel discussions, meaningful conversations, and insightful sessions.

Honored to bring the voice of the community oncologist to the table — while also representing as a subspecialist in breast and GU cancers. Bridging academic innovation with real-world practice is more than a talking point in the community it affects everyday lives.

Highlights from yesterday’s metastatic breast cancer data that stood out:

T-DXd re-challenge in a diverse, real-world population (Hope Rugo)

– Rechallenge after Grade 1 ILD showed no Grade 5 ILD events.

– Median time to ILD: 5 months | Median duration on therapy: 215 days.

– 61% had dose reductions, yet clinical benefit maintained.

– A reminder: CT chest at 6 weeks, no longer than 9 weeks

OPTI-TROP5 (Sacituzumab Tirumotecan):

– Novel Trop-2–directed ADC with a belotecan-based topoisomerase I inhibitor payload.

– In mTNBC (PD-L1–agnostic): ORR 45.4%, DCR 92%.

– Median PFS: 6.7 mo vs 2.5 mo (HR 0.32) | OS not reached vs 9.4 mo (HR 0.53).

– Unique AEs: Cytopenias, stomatitis (10%), and rare but notable exophthalmia & blurred vision (3.1%).

– Manageable toxicity with promising durability and activity in a challenging population.

– Question: How does it stack up against sacituzumab govitecan in this setting?

KAT6 inhibitor + fulvestrant (Patricia LoRusso, Yale Cancer Center):

– First-in-class, novel KAT6 inhibitor (PF-07248144) in Phase I dose escalation/expansion.

– In ER+/HER2– MBC post-CDK4/6, combination showed:

→ ORR 37.2%, median PFS 10.7 months.

– Safety: Dysgeusia (84.6%, mostly Grade 1); Grade ≥3 neutropenia ~37%.

– Question: Where does this fit in with new oral SERDs?

From hallway chats to clinical deep-dives, the spirit of collaboration and shared purpose was everywhere. Whether you’re at a major academic center or, like me, in a community setting — we’re all pushing oncology forward, together.

Let’s keep the momentum going! If we met today — let’s keep in touch. If we haven’t yet — come find me!”

Kurian reflected on Day 1 of ASCO25, focusing on new clinical findings in metastatic breast cancer, including data on T-DXd re-challenge, OPTI-TROP5, and a KAT6 inhibitor plus fulvestrant combination.

More posts featuring Matthew Kurian.

ADC ASCO25 belotecan Breast Cancer cancer cytopenias Dysgeusia fight against cancer Global fight against cancer Grade 1 ILD GU cancers HER2 Hope Rugo KAT6 inhibitor Matthew Kurian neutropenia OncoDaily Oncology OPTI-TROP5 Patricia LoRusso PD-L1–agnostic Sacituzumab Tirumotecan SERDs stomatitis T-Dxd topoisomerase University of Kentucky College of Medicine Yale Cancer Center

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself